NEWS OF NOTE
IAEA Student Essay Competition
- IAEA Nuclear Safety Essay Competition for Students and Early Career Professionals. Are you a student or young professional interested in nuclear safety and related topics? Then the IAEA invites you to participate in this essay contest associated with the upcoming international conference looking at a decade of progress after Fukushima-Daiichi! This essay competition aims to promote creative and innovative thinking and highlight the critical role that the next generation will play in sustaining and ensuring a safe future for the peaceful uses of nuclear technology in areas such as nuclear power, food and agriculture, water management, and human health. Students and professionals (up to 30 years) pursuing a degree in a related field, or with a personal or professional interest in nuclear safety, are encouraged to participate.
RNCP-Supported Resource for NHP Samples and Data
- Wake Forest Nonhuman Primate (NHP) Radiation Late Effects Survivor Cohort. Since 2007, this core has served as a national resource for the long-term care and study of animals after irradiation. Because of the high degree of genetic and physiologic similarity of NHPs to human beings, this resource is a critical component of translational long-term assessment of candidate radiation mitigators, in an experimental setting under which relevant doses of whole-body irradiation and partial body irradiation with 5% bone marrow sparing can be studied in otherwise healthy subjects. Researchers can request access to samples and data from these animals (more information at the site), and explore collaboration opportunities.
- Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed) (NOT-CA-21-081) The National Cancer Institute (NCI) plans to publish a Funding Opportunity Announcement for the "Cancer Target Discovery and Development (CTD2)” Initiative (U01). CTD2 will promote efforts to radically improve our understanding of the underlying etiology of cancer initiation, progression, and metastasis and to exploit this knowledge in clinically relevant context which includes intra-tumor heterogeneity, tumor microenvironment and other factors that result in "innate" or acquired treatment resistance. Specifically, the program is focused on identifying and understanding pathways that influence cancer phenotypes (including understanding the function of the genes/targets which are essential in cancer transformation and maintenance); perturbagens that can modulate such pathways; biomarkers predicting responses to treatments, prognosis, and other aspects of cancer etiology that need to be understood in order to develop effective treatments in the future and how to predict them.
· New NASA Joint Funding Opportunity with the RNCP (also includes NIAID, NCATS, NCI, BARDA & FDA)
- NNH21ZDA015N NASA Research Announcement: Extended Longevity of 3D Tissues and Microphysiological Systems for Modeling of Acute and Chronic Exposures to Stressors (Contract). This NASA Research Announcement (NRA), “Extended Longevity of 3D Tissues and Microphysiological Systems for Modeling of Acute and Chronic Exposures to Stressors”, is a multi-organizational effort sponsored by NASA’s Space Biology Program, NASA’s Human Research Program, the NIH’s National Center for Advancing Translational Sciences (NCATS), the National Institute of Allergy and Infectious Diseases (NIAID), and National Cancer Institute (NCI), the Biomedical Advanced Research and Development Authority (BARDA), and the Food and Drug Administration (FDA), to solicit for research in support of common cross-organizational goals. This NRA is focused on adapting existing 3D tissues and microphysiological systems (MPS), also known as “tissue chips” or “organs-on-chips”, to extend the current longevity of the 3D tissues and MPS to at least 6 months. Pre-Proposers Conference: June 8, 2021; Step-1 Proposals Due: June 28, 2021; Step-2 Proposals Due: September 14, 2021; Estimated Selection Announcement Date: January 2022.
- Emerging Science and Technology in Transplantation (U01 Clinical Trial Not Allowed) (RFA-AI-21-016) NIAID. The purpose of this Funding Opportunity Announcement is to solicit applications from institutions or organizations to participate in a cooperative research group focused on transplantation immunology research in three priority areas: 1) microbiota; 2) intravital imaging; and 3) targeted therapeutic delivery. This FOA stimulates the formation of interdisciplinary collaborations and facilitates the application of new scientific developments and technologies to the field of transplant immunology. Applying these advances to transplantation science will provide novel insights into the nature of alloimmune responses and reveal new avenues to diagnose, treat and prevent allograft rejection or promote immunologic tolerance. Application Receipt Date(s): September 03, 2021
- Radiation-Induced Immune Dysfunction (U01 Clinical Trial Not Allowed) RFA-AI-21-019. The purpose of this initiative is to investigate the effects of radiation exposure on the immune system and explore possible treatments for radiation-induced immune dysfunction. Research gaps exist in understanding the mechanisms of injury and repair with regard to radiation-induced immune system dysfunction, and these gaps must be addressed to better develop medical countermeasures (MCMs) for radiation exposure. Through this initiative, the RNCP will support development of animal models for immune-targeted radiation injuries, studies to better understand radiation impacts on the immune system (including immune system-mediated multi-organ injury), and identification of immune-specific pathways targeted by radiation, as well as biomarkers of exposure and mitigators/treatments that target immune-related radiation response pathways. Applications are due August 24, 2021.
- NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed) (PAR-21-209) ESI CounterACT R21 projects may be exploratory, applied, proof of principle, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals.
- The International Conference on the Development of Preparedness for National and International Emergency Response (EPR2021), with be held from 11 – 15 October 2021 in Vienna, Austria. (if COVID-19 restrictions persist the Conference will be held virtually on the same dates). The purpose of the Conference is to foster exchange of information and enhance global awareness on various EPR topics through the discussion of both the progress made at national and international levels and the challenges encountered, by sharing experiences, evaluating current trends, technologies and lessons in EPR and identifying key priorities in further improving readiness for nuclear and radiological incidents and emergencies, regardless whether they arise from an accident, natural disaster, negligence, nuclear security event or any other cause. Further information about the Conference can be found here.
- Learn the purpose and function of software tools developed by scientific groups within NATO. These tools either allow an integrated estimation of dose (BAT, WinFRAT), or the prediction of ARS severity based on changes in blood cell counts (H-module) in the first days after an exposure to ionizing radiation. You will be introduced into these tools primarily by those who developed them, so that you will receive firsthand information about their strengths and limitations. Y
Article: “Impact of aging on gene expression response to x-ray irradiation using mouse blood”
Dr. Sally Amundson and colleagues demonstrate the impact of aging on the gene expression profile in mice exposed to radiation. [13May2021 Sci Rep.]
Constantinos G Broustas, Axel J Duval, Sally A Amundson
- Postdoctoral Research Scholar (NC State University College of Veterinary Medicine) Raleigh, NC. The successful candidate will lead an NIH-funded project studying the role of cold-sensing (TRPM8-expressing) neurons in the pain which accompanies chemoradiotherapy associated oral mucositis. The project involves benchtop cell culture experiments, studies using genetically engineered mouse models, and a pair of pilot clinical studies wherein pain signaling will be studied in both dogs (NC State College of Veterinary Medicine) and humans (Duke Cancer Institute) undergoing treatment for head and neck cancer. This will be a two-year minimum position.
- Interim Assistant Director Radiation Therapy – Oncology (Clinical Management Consultants) Dover, DE. The Interim Assistant Director of Radiation Therapy Oncology will report to the Senior Director of Oncology Operations and be responsible for directly supervising and overseeing the Radiation Oncology Department while maintaining quality standards and ensuring patient safety. Staff management, budgetary oversight, clinical operations, quality control, and strategic growth will all fall under the responsibility of this manager.
- Assistant Director Radiation Therapy Oncology ARRT (Clinical Management Consultants) Dover, DE. The Assistant Director of Radiation Oncology will report to the Senior Director of Oncology Operations and be responsible for directly supervising and overseeing the Radiation Oncology Department while maintaining quality standards and ensuring patient safety. Staff management, budgetary oversight, clinical operations, quality control, and strategic growth will all fall under the responsibility of this manager.
- NASA is hiring a Chief Scientist for the Human Research Program
- External to NASA (IPA opportunity): https://www.nasa.gov/press-release/announcement-of-intergovernmental-personnel-act-ipa-opportunity-human-research-program
- External to NASA (Civil Servant Opportunity, SL): https://www.usajobs.gov/GetJob/ViewDetails/601512100
- Internal to NASA (Civil Servant Opportunity, SL):: https://www.usajobs.gov/GetJob/ViewDetails/601512400
More Content via the CMRC Website:
SEND US your publications, events, news, and announcements.